The impact of sodium-glucose Cotransporter-2 inhibitors on lipid profile: A meta-analysis of 28 randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of sodium-glucose Cotransporter-2 inhibitors on lipid profile: A meta-analysis of 28 randomized controlled trials

Published:2023-11 Issue: Volume:959 Page:176087
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Fan Gang^ORCID,Guo Dian long,Zuo Hong

Publisher

Elsevier BV

Subject

Pharmacology

Reference60 articles.

1. Long-term efficacy and safety of Ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: vertis mono extension study;Aronson;Diabetes Obes. Metabol.,2018

2. Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: a 24‐week, Randomized Controlled Trial;Bae;Diabetes Obes. Metabol.,2020

3. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis;Beitland;Intensive Care Med.,2015

4. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease;Bhattarai;JAMA Netw. Open,2022

5. Long-term efficacy and safety of Canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes;Bode;Diabetes Obes. Metabol.,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients;Journal of Clinical Medicine;2024-08-21

2. Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial;Frontiers in Endocrinology;2024-07-19

3. Is Tirzepatide the New Game Changer in Type 2 Diabetes?;Endocrines;2024-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3